MX2024004871A - Compuesto que contiene piridilo. - Google Patents
Compuesto que contiene piridilo.Info
- Publication number
- MX2024004871A MX2024004871A MX2024004871A MX2024004871A MX2024004871A MX 2024004871 A MX2024004871 A MX 2024004871A MX 2024004871 A MX2024004871 A MX 2024004871A MX 2024004871 A MX2024004871 A MX 2024004871A MX 2024004871 A MX2024004871 A MX 2024004871A
- Authority
- MX
- Mexico
- Prior art keywords
- pyridyl
- containing compound
- preparation
- drug
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111269381 | 2021-10-29 | ||
| CN202210233624 | 2022-03-10 | ||
| CN202210849103 | 2022-07-19 | ||
| CN202211274771 | 2022-10-18 | ||
| PCT/CN2022/128251 WO2023072248A1 (zh) | 2021-10-29 | 2022-10-28 | 含吡啶基的化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004871A true MX2024004871A (es) | 2024-05-06 |
Family
ID=86159245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004871A MX2024004871A (es) | 2021-10-29 | 2022-10-28 | Compuesto que contiene piridilo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002472A1 (https=) |
| EP (1) | EP4424676A4 (https=) |
| JP (1) | JP2024539922A (https=) |
| KR (1) | KR20240090588A (https=) |
| CN (1) | CN118055924A (https=) |
| AU (1) | AU2022376773A1 (https=) |
| CA (1) | CA3235436A1 (https=) |
| IL (1) | IL312179A (https=) |
| MX (1) | MX2024004871A (https=) |
| TW (1) | TW202321220A (https=) |
| WO (1) | WO2023072248A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121039118A (zh) * | 2023-04-28 | 2025-11-28 | 正大天晴药业集团股份有限公司 | 含三唑基的化合物 |
| WO2026082075A1 (zh) * | 2024-10-15 | 2026-04-23 | 杭州百诚医药科技股份有限公司 | 丙烯酰胺类化合物及其医药用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03421B (me) * | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
| US10526295B2 (en) * | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2019232724A1 (en) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| CN110592141B (zh) * | 2018-06-13 | 2023-07-07 | 中国科学院上海有机化学研究所 | 用于调控基因编辑效率的化合物及其应用 |
| WO2020092965A1 (en) * | 2018-11-01 | 2020-05-07 | Karyopharm Therapeutics Inc. | E2f1 as a biomarker for treatments using xpo1 inhibitors |
| WO2021252900A1 (en) * | 2020-06-11 | 2021-12-16 | Karyopharm Therapeutics Inc. | Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients |
| CN112538069A (zh) * | 2020-11-05 | 2021-03-23 | 苏州艾和医药科技有限公司 | 一种氮唑类衍生物或其药物可接受盐及其制备方法和用途 |
| CN113045550A (zh) * | 2021-03-12 | 2021-06-29 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
| CN113248474A (zh) * | 2021-05-24 | 2021-08-13 | 王能能 | 五元氮唑杂环衍生物及其制备方法和用途 |
-
2022
- 2022-10-28 CA CA3235436A patent/CA3235436A1/en active Pending
- 2022-10-28 WO PCT/CN2022/128251 patent/WO2023072248A1/zh not_active Ceased
- 2022-10-28 AU AU2022376773A patent/AU2022376773A1/en active Pending
- 2022-10-28 KR KR1020247016666A patent/KR20240090588A/ko active Pending
- 2022-10-28 IL IL312179A patent/IL312179A/en unknown
- 2022-10-28 EP EP22886123.3A patent/EP4424676A4/en active Pending
- 2022-10-28 US US18/703,482 patent/US20250002472A1/en active Pending
- 2022-10-28 JP JP2024523981A patent/JP2024539922A/ja active Pending
- 2022-10-28 CN CN202280066733.8A patent/CN118055924A/zh active Pending
- 2022-10-28 MX MX2024004871A patent/MX2024004871A/es unknown
- 2022-10-28 TW TW111141120A patent/TW202321220A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023072248A1 (zh) | 2023-05-04 |
| AU2022376773A1 (en) | 2024-05-23 |
| JP2024539922A (ja) | 2024-10-31 |
| CN118055924A (zh) | 2024-05-17 |
| CA3235436A1 (en) | 2023-05-04 |
| IL312179A (en) | 2024-06-01 |
| TW202321220A (zh) | 2023-06-01 |
| EP4424676A1 (en) | 2024-09-04 |
| US20250002472A1 (en) | 2025-01-02 |
| KR20240090588A (ko) | 2024-06-21 |
| EP4424676A4 (en) | 2025-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002332A (es) | Derivado heterociclico inhibidor que contiene nitrogeno, y metodo de preparacion y su uso. | |
| PH12022551574A1 (en) | Egfr inhibitors | |
| PH12022553313A1 (en) | Five-membered heteroaromatic imidazole compound and use thereof | |
| MX2025004604A (es) | Nuevos compuestos triheterociclicos | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| TN2019000263A1 (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| PH12019550224A1 (en) | Antitumoral compounds | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| GEAP202014978A (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
| TW200519111A (en) | N3-substituted imidazopyridine C-KIT inhibitors | |
| SG11201906435SA (en) | Pyrimidine compound and pharmaceutical use thereof | |
| ZA202200905B (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
| AU2020320233A8 (en) | Anti-HER2/anti-4-1BB bispecific antibody and use thereof | |
| MX2024004871A (es) | Compuesto que contiene piridilo. | |
| CR20240014A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2024002261A (es) | Molecula de union de fap/cd40 y uso medicinal de la misma. | |
| EP4119563A3 (en) | Macrocyclic compound and uses thereof | |
| WO2020154499A8 (en) | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity | |
| PH12021553058A1 (en) | Tricyclic compounds and their use | |
| MX2025013480A (es) | Compuestos heterocíclicos que contienen nitrógeno y uso de los mismos |